Stifel Reiterates Buy on Spyre Therapeutics, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Alex Thompson has reiterated a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $36 to $54, indicating a positive outlook on the company's stock.
March 26, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Alex Thompson has reiterated a Buy rating on Spyre Therapeutics and raised the price target from $36 to $54.
The reiteration of a Buy rating combined with a significant increase in the price target by a reputable analyst suggests a strong bullish sentiment towards Spyre Therapeutics. This is likely to positively influence investor perception and could lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100